3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
3
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
pembrolizumab
2
Sunitinib
2
Cisplatin
2
Brentuximab Vedotin
2
tremelimumab
1
pralsetinib
1
keyhole-limpet hemocyanin
1
durvalumab
1
Tetanus Toxoid
1
Sirolimus
1
Plicamycin
1
Pemetrexed
1
Paclitaxel
1
Genistein
1
Gemcitabine
1
Gefitinib
1
Erlotinib Hydrochloride
1
Epirubicin
1
Carboplatin
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms, Germ Cell and Embryonal
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts